You searched for "neovascular"
Licence to save: a UK survey of anti-VEGF use for the eye
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...AI can identify treatment gaps for patients with macular disease, study shows
Using artificial intelligence (AI) in eye clinics could reduce both undertreatment and overtreatment of neovascular or ‘wet’ age-related macular degeneration (AMD). AMD is the leading cause of irreversible vision loss in older people and accounts for around 1 in 10...Corporate M&A pace gathers momentum
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...Eye Capacity: clinical need should drive ophthalmic service provision
Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...
OCT angiography metrics in children
This prospective study aimed to quantify the vessel density of both the macular and optic nerve and foveal avascular zone (FAZ) values in 92 normal eyes of 92 children (42 boys, 50 girls) aged 13.4 ±2.65 years (seven to 18)....21st Century retinal laser treatment in the anti-VEGF era
In today’s world, macular laser treatment has a vital role in the treatment of diabetic macular oedema (DMO). DMO is one of the most common causes of visual impairment. Despite expensive intravitreal treatment courses of anti-VEGF, many will agree that...Headaches in ophthalmology (part 1)
Ophthalmologists see a large number of patients with headaches or facial pain in the ophthalmic outpatient clinics or in emergency clinics. Over two articles, I will discuss several causes of headaches, ocular manifestations and proposed management and referral options. It...More sensitive visual acuity test for age-related macular degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...The role of injection assistant devices in establishing a nurse-led AMD service
The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...
